


Abstract 424 Table 1 CVE in women with SLE born in Sweden between 1951-1971.

	Non-parous (n=915)	Preterm < 34/40 (n=194)	Delivery ≥ 34/40 (n=2,119)
CVE, n (%)	138 (15.1)	30 (15.5)	166 (7.9)
Age at 1st CVE, years (IQR)	41 (33–48)	40.5 (31–48)	46 (40–51)
Incidence, per 1,000 person-years (95% CI)	3.44 (2.91–4.07)	3.53 (2.47–5.05)	1.75 (1.50–2.03)
Adjusted hazard of a CVE, adjHR* (95% CI)	1.42 (1.14–1.78)	1.22 (1.09–1.37)	1.0
CI – confidence interval; * adjusted for CV risk factors and SLE-related morbidity.			



Abstract 424 Figure 1

52% respectively, $p=0.044$) (Figure 1). LN diagnosed in 1998–2013 was associated with 5 year and 10 year relapse-free survival rates of 93% and 86% respectively, compared with 81% and 66% respectively ($p=0.017$) for patients who presented in 1983–1997 (Figure 2).

Conclusions The risk of renal relapse has decreased in the current era, probably attributed to replacement of AZA with MPA as maintenance treatment.

428

PRE-EMPTIVE TREATMENT FOR ASYMPTOMATIC SEROLOGICAL REACTIVATION IN LUPUS NEPHRITIS PATIENTS – IMPACT ON CLINICAL FLARE RATE AND RENAL FUNCTION

DYH Yap*, MK Ma, MM Mok, GC Chan, LP Kwan, TM Chan. *Queen Mary Hospital- The University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong S.A.R*

10.1136/lupus-2017-000215.428

Background and aims Pre-emptive immunosuppressive treatment for asymptomatic serological activation (ASR) in lupus nephritis (LN) patients remains controversial, and its impact on subsequent flare rate and long-term renal outcome is unclear.

Methods We conducted a retrospective study on all episodes of ASR in 1993–2015 to investigate the relationship between pre-emptive treatment and subsequent clinical flares and renal outcomes.

Results 138 episodes of ASR occurred in 98 patients during the study period. 53 episodes (in 38 patients) were treated with pre-emptive increase in immunosuppression while 85 episodes (in 60 patients) were not, and patients were followed up for 88.8 ± 77.3 months and 82.8 ± 89.7 months respectively after ASR occurred. Pre-emptive treatment was associated with superior renal relapse-free survival (100%, 95% and 90% at 6, 12 and 24 months respectively) compared with no pre-emptive treatment (93%, 68% and 65% respectively, $p=0.007$), while extra-renal relapse-free survival did not differ between the two groups (Figure 1). 5 (9.4%) of 53 ASR episodes treated pre-emptively developed renal flare at 14.3 ± 6.7 months after ASR. Patients who received pre-emptive treatment for ASR and did not develop renal flares showed also better eGFR slope ($+0.54 \pm 0.43$ ml/min/1.73 m²/year) compared with the non-pre-emptive groups with or without renal flares (-2.11 ± 0.50 and -1.00 ± 0.33 ml/min/1.73 m²/year respectively, $p=0.001$ and 0.012) (Figure 2). Pre-emptive treatment was associated with more gastrointestinal adverse events related to increased mycophenolate dose ($p=0.031$). Infection rate was similar between both groups.

Conclusions Renal flares have a negative impact on renal function and pre-emptive treatment for ASR could reduce renal flare risk and its consequences in LN patients.

429

ANTIPHOSPHOLIPID ANTIBODY POSITIVITY AND RELATED CLINICAL CHARACTERISTICS IN KOREAN LUPUS PATIENTS

¹S Nam, ¹D Kim*, ¹SK Cho, ²KE Lee, ²DJ Park, ²SS Lee, ¹YK Sung. ¹Hanyang University Hospital for Rheumatic Diseases, Rheumatology, Seoul, Republic of Korea; ²Chonnam national university medical school and hospital, Rheumatology, Gwangju, Republic of Korea

10.1136/lupus-2017-000215.429